ALT5 Sigma Delays Planned Spin-Off Of Alyea Therapeutics, Continues To Explore Strategic Options; Alyea Spin-Off Will Not Occur On June 2, 2025, May Not Occur Under Previously Disclosed Timeline

Author: Benzinga Newsdesk | October 01, 2025 04:19pm

Commencing in late 2024, ALT5 Sigma Corporation (the "Company") had disclosed a strategic plan to separate into two distinct companies and its intent to finance Alyea Therapeutics Corporation ("Alyea") separately from the Company in a manner that was to be determined. As a result of several factors, a potential spin-off, or similar transaction, of Alyea will not occur with the previously disclosed June 2, 2025, record date and may not occur under the previously disclosed timeline. To the extent the Company undertakes a spin-off or similar transaction of Alyea, it will announce at an appropriate time the relevant information, including a future record date, structure, and timing. The Company remains encouraged by the science and potential of Alyea's non-addictive pain treatment patents and potential progression to the next stage of clinical trials across its prospective products, which could increase Alyea's realizable value. The Company continues to evaluate its strategic options both to maximize and realize the value of Alyea.

Posted In: ALTS